Literature DB >> 8940483

Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans.

T F Patterson1, W R Kirkpatrick, S G Revankar, R K McAtee, A W Fothergill, D I McCarthy, M G Rinaldi.   

Abstract

A simple screening method for fluconazole susceptibility using CHROMagar Candida with fluconazole was compared with the National Committee for Clinical Laboratory Standards (NCCLS) macrobroth method. In this agar dilution method, susceptible Candida albicans colonies are smaller on medium with fluconazole than on fluconazole-free medium. Yeasts with decreased susceptibility have normal-sized colonies on medium containing fluconazole. On agar with 16 micrograms of fluconazole per ml, 32 of 34 strains with NCCLS MICs of > or = 16 micrograms/ml were correctly predicted, as were 66 of 68 with MICs of < 16, an agreement of 96%. On agar with 8 micrograms of fluconazole per ml, 38 of 41 isolates with MICs of > or = 8 were correctly predicted, as were 59 of 61 isolates with MICs of < 8, an agreement of 95%. This agar dilution methods appears to highly correlate with NCCLS macrobroth methods for detection of C. albicans and may be an effective screen for fluconazole susceptibility.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940483      PMCID: PMC229494          DOI: 10.1128/jcm.34.12.3237-3239.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

Review 1.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

Authors:  S Redding; J Smith; G Farinacci; M Rinaldi; A Fothergill; J Rhine-Chalberg; M Pfaller
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

Review 3.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

4.  Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; O P Dib; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

5.  Differential and enrichment media for selective culture and recognition of yeast species from clinical material.

Authors:  B Louwagie; I Surmont; J Verhaegen; F Odds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

6.  Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.

Authors:  J H Rex; M A Pfaller; A L Barry; P W Nelson; C D Webb
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype.

Authors:  L Millon; A Manteaux; G Reboux; C Drobacheff; M Monod; T Barale; Y Michel-Briand
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

9.  CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species.

Authors:  F C Odds; R Bernaerts
Journal:  J Clin Microbiol       Date:  1994-08       Impact factor: 5.948

10.  Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis.

Authors:  M A Pfaller; J Rhine-Chalberg; S W Redding; J Smith; G Farinacci; A W Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

View more
  14 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients.

Authors:  J L Lopez-Ribot; R K McAtee; S Perea; W R Kirkpatrick; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Comparative evaluation of National Committee for Clinical Laboratory Standards broth macrodilution and agar dilution screening methods for testing fluconazole susceptibility of Cryptococcus neoformans.

Authors:  W R Kirkpatrick; R K McAtee; S G Revankar; A W Fothergill; D I McCarthy; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

4.  Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Authors:  S Perea; J L López-Ribot; W R Kirkpatrick; R K McAtee; R A Santillán; M Martínez; D Calabrese; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer.

Authors:  Spencer W Redding; William R Kirkpatrick; Brent J Coco; Lee Sadkowski; Annette W Fothergill; Michael G Rinaldi; Tony Y Eng; Thomas F Patterson
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

6.  Loss of in vitro resistance in Candida glabrata following discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient.

Authors:  Steven D Westbrook; Nathan P Wiederhold; Ana C Vallor; Susann Kotara; Stella Bernardo; Samuel A Lee; William R Kirkpatrick; Juan J Toro; Cesaro Freytes; Thomas F Patterson; Spencer W Redding
Journal:  Med Mycol       Date:  2010-05       Impact factor: 4.076

7.  Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

8.  Detection of fluconazole-resistant isolates of Candida glabrata by using an agar screen assay.

Authors:  Susan M Nelson; Charles P Cartwright
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  J L Lopez-Ribot; R K McAtee; L N Lee; W R Kirkpatrick; T C White; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.

Authors:  Marcos Martinez; José L López-Ribot; William R Kirkpatrick; Brent J Coco; Stefano P Bachmann; Thomas F Patterson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.